GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AKBA · Sep 30, 2024

Akebia Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-24-045979General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

102.48% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.01% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-17.89% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-10.98% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

54.75% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

62.16% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-33.41% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

22.68% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.40% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesHistory building

Sep 30, 20230/8 normalizedLevel 3 Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/9 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/9 normalizedLevel 3 Sep 30, 20257/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20268/9 normalizedLevel 3 Jun 30, 20268/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 87.13%
Current: 102.48%
Delta: 15.35%

Cash Generation Increased

Previous: -23.06%
Current: -17.89%
Delta: 5.17%

Inventory Pressure Increased

Previous: 54.69%
Current: 54.75%
Delta: 0.06%

Margin Increased

Previous: 60.94%
Current: 62.16%
Delta: 1.22%

Profitability Decreased

Previous: -19.99%
Current: -33.41%
Delta: -13.42%

R And D Intensity Increased

Previous: 17.52%
Current: 22.68%
Delta: 5.16%

Sbc Intensity Decreased

Previous: 4.75%
Current: 4.40%
Delta: -0.35%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AKBA Fundamental State →Transitioned To · AKBA Fundamental State →Transitioned To · AKBA BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · AKBA CASH_GENERATION_INCREASED →Transitioned To · AKBA INVENTORY_PRESSURE_INCREASED →Transitioned To · AKBA MARGIN_INCREASED →Transitioned To · AKBA PROFITABILITY_DECREASED →Transitioned To · AKBA R_AND_D_INTENSITY_INCREASED →Transitioned To · AKBA SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.